Urticaria: modern data on pathogenesis, classification and therapy

A.A. Cheburkin

Federal State Budgetary Educational Institution of Further Professional Education “Russian Medical Academy of Continuous Professional Education” of the Ministry of Healthcare of the Russian Federation, Moscow, Russia

ALLERGOLOGY AND IMMUNOLOGY IN PEDIATRICS, Volume 54 • Number 3 • September 2018, pp. 4 – 13
DOI: 10.24411/2500-1175-2018-00011

In recent years, it has been revealed that, despite an identical clinical picture, there is a wide range of subtypes of urticaria and they differ depending on not only provocative factors, but also have different pathogenetic mechanisms in a basis. Urticaria needs to be differentiated from other diseases where wheals, angioedema are symptoms of the main disease including urticarial vasculitis, anaphylaxis, some autoinflammatory syndromes, hereditary angioedema. In this case the basic method of treatment is therapy of the main disease. At a spontaneous urticaria a basis of therapy are H1-anthistamines, from which it is distinguished cetirizine because of its specific properties: besides antihistaminic effect his anti-inflammatory action is established.

  1. The diagnosis and management of acute and chronic urticaria: 2014 update /J.A. Bernstein, D.M. Lang, D.A. Khanetal. // J. Allergy Clin.Immunol. 2014. Vol. 133. P. 1270–1277.
  2. Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous (‘idiopathic’) urticaria/ A.B.Kay, P.Clark, M.Maurer et al. // Br. J.Dermatol. 2015. Vol. 172, № 5. P. 1294–1302.
  3. Calcitonin gene-related peptide and vascular endothelial growth factor are expressed in lesional but not uninvolved skin in chronic spontaneous urticaria/ A.B.Kay, S.Ying, E.Ardelean et al. // Clin. Exp. Allergy. 2014.Vol.44, № 8. P. 1053–1060.
  4. Basophil recruitment and activation in inflammatory skin diseases /Y.Ito, T.Satoh, K. Takayamaet al. // Allergy. 2011. Vol.66, № 8. P. 1107–1113.
  5. Enhanced P-selectin expression in chronic and dermographicurticaria/ T.Zuberbier,D.Schadendorf, N. Haas et al. // Int. Arch. Allergy Immunol. 1997. Vol.114, № 1. P. 86–89.
  6. Elevations in vascular markers and eosinophils in chronic spontaneous urticarial weals with low-level persistence in uninvolved skin /A.B.Kay, S.Ying, E.Ardelean et al. // Br. J.Dermatol. 2014. Vol.171, № 3. P. 505–511.
  7. Epidemiology of urticaria in infants and young children in Germany – results from the German LISAplus and GINIplus birth cohort studies /I.Bruske, M.Standl, S.Weidinger et al. // Pediatr. Allergy Immunol. 2014. Vol.25. P. 36–42.
  8. Clinical features and natural history of physical urticaria in children /G.Khakoo, A.Sofianou-Katsoulis, M.R. Perkin et al. // Pediatr. Allergy Immunol. 2008.Vol.19. P. 363–366.
  9. Prognosis of chronic spontaneous urticaria in 117 patients not controlled by a standard dose of antihistamine / M.Hiragun, T.Hiragun, S.Miharaet al. // Allergy. 2013. Vol.68. P. 229–235.
  10. Chronic urticaria: etiology and natural course in children /U.M.Sahiner, E.Civelek, A.Tuncer et al. // Int. Arch. Allergy Immunol. 2011. Vol.156. P. 224–30.
  11. Zitelli K.B., Cordoro K.M. Evidence-based evaluation and management of chronic urticaria in children. // Pediatr.Dermatol. 2011. Vol.28. P. 629–639.
  12. An overview of chronic urticaria in children, with an evidence-based approach /Caffarelli C., Cuomo B., Cardinale F. et al.
  13. Aetiological factors associated with chronic urticaria in children: a systematic review // ActaDerm.Venereol. 2013. Vol.93. P. 268–272.
  14. Zitelli K.B., Cordoro K.M. Evidence-based evaluation and management of chronic urticaria in children // Pediatr.Dermatol. 2011. Vol.28. P. 629–639.
  15. Aetiological factors associated with chronic urticaria in children: a systematic review / C.Caffarelli, B.Cuomo, F.Cardinale et al. // ActaDerm.Venereol. 2013. Vol.93. P. 268–272.
  16. Management of childhood urticaria: current knowledge and practical recommendations / H.Pite, B.Wedi, L.M. Borrego et al. // ActaDerm.Venereol. 2013. Vol.93. P. 500–508.
  17. An updated and accurate review of the pharmacological and non-pharmacological management of childhood urticaria/ Longo G., Berti I., Burks A.W.et al. IgE-mediated food allergy in children. // Lancet. 2013.Vol.382. P. 1656–1664.
  18. Urticaria and urticaria related skin condition/disease in children / E.Novembre, A.Cianferoni, F. Mori et al.// Eur. Ann. Allergy Clin. Immunol. 2008.Vol.40. P. 5–13.
  19. Greaves M. Chronic urticaria// J Allergy Clin. Immunol. 2000. Vol.105.P. 664–672.
  20. Solar urticaria: a report on 57 cases / G.Monfrecola, E.Masturzo, A.M.Riccardo et al. // Am. J. Contact.Dermatol. 2000. Vol.11. P. 89–94.
  21. Luong K.V., Nguyen L.T. Aquagenicurticaria: report of a case and review of the literature // Ann. Allergy Asthma Immunol. 1998. Vol.80.P. 483–485.
  22. Association between urticaria and virus infections: A systematic review /E.Imbalzano, M.Casciaro, S.Quartuccio et al. // Allergy Asthma Proc. 2016. Vol.37, № 1. P. 18–22.
  23. Urticaria and bacterial infections / P.L.Minciullo, A.Cascio, G.Barberiet al.// Allergy, Asthma Proc. 2014. Vol.35, № 4. P. 295–302.
  24. Helicobacter pylori as a Possible Bacterial Focus of Chronic Urticaria /S.Wustlich, R.Brehler, T.A. Luger et al.// Dermatology. 1999. Vol.198. P. 130–132.
  25. A neglected cause for chronic spontaneous urticaria in children: Helicobacter pylori/ A.Z.Akelma, M.N.Cizmeci, E.Mete et al. // Allergol.Immunopathol. (Madr.).2015, May-Jun. Vol.43, № 3. P. 259–263.
  26. Chronic spontaneous urticaria and internal parasites–a systematic review /P.Kolkhir, G.Balakirski, H.F.Merket al.// Allergy. 2016. Vol.71, № 3. P. 308–322.
  27. Hill D.R., Nash T.E. Intestinal flagellate and ciliate infections / In Guerrant R.L., Walker D.H., Weller P.F. (eds): Tropical Infectious Diseases. Philadelphia, ChurchillLivingstone, 1999.P. 703–719.
  28. Дерматозы и паразитарные болезни у детей и подростков : практическое пособие. Екатеринбург: Издательство Уральского университета, 2006. 61 с.
  29. I.A. Khan, M.A. Khan. Urticaria and Enteric Parasitosis: an agonizing condition // Med. Channel. 1999.Vol.5, № 4. P. 25–28.
  30. EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria /G.N.Konstantinou, R.Asero, M. Ferrer et al. // Allergy. 2013. Vol.68, № 1. P. 27–36.
  31. Chronic idiopathic urticaria: comparison of the clinical features of patients with and without anti-FeRI or anti-IgE autoantibodies /R.A.Sabroe, P.T.Seed, D.M.Francis et al.// J. Am. Acad.Dermatol. 1999. Vol.40.P. 443–450.
  32. Successful treatment of chronic idiopathic urticaria associated with thyroid autoimmunity /P.Gaig, P.Garcia-Ortega, E. Enrique et al.// J. Invest.Allergol.Clin.Immunol. 2000. Vol.10. P. 342–345.
  33. Thyroid autoimmunity in chronic urticarial /D.Zauli, G.Deleonarid, S.Goderaro et al. // Allergy Asthma Proc. 2001. Vol.22.P. 93–95.
  34. Kowalski M.L., Woessner K., Sanak M. Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug-related urticaria and angioedema // J. Allergy Clin.Immunol. 2015. Vol.136, № 2. P. 245–251.
  35. Plasmapheresis for severe, unremitting, chronic urticarial /C.E.Grattan, D.M.Francis, N.G.Slater et al.// Lancet. 1992. Vol.339(8801). P. 1078–1080.
  36. A Popular myth – low-histamine diet improves chronic spontaneous urticaria– fact or fiction?/ N.Wagner, D.Dirk, A.Peveling-Oberhag et al. // J. Eur. Acad.Dermatol.Venereol. 2016. Vol.31, № 4. P. 650–655.
  37. Can On-demand Non-sedating Antihistamines Improve Urticaria Symptoms? A Double-blind, Randomized, Single-dose Study /K.Weller, E.Ardelean, E.Scholzet al.// ActaDerm.Venereol. 2013. Vol.93, № 2. P. 168–174.
  38. Vonakis B.M., Saini S.S. New concepts in chronic urticaria// Curr.Opin.Immunol. 2008. Vol.20, № 6. P. 709–716.
  39. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper/ M.K.Church, M.Maurer, F.E. Simons et al.// Allergy. 2010. Vol.65, № 4. P. 459–466.
  40. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) /J.Bousquet, N.Khaltaev, A.A.Cruz et al. // Allergy. 2008. Vol.63.Suppl 86: P. 8–160.
  41. The EAACI/GA²LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update Article in Allergy, January 2018.
  42. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticarial /M.Staevska, T.A.Popov, T.Kralimarkova et al. // J. Allergy Clin.Immunol. 2010. Vol.125, № 3. P. 676–682.
  43. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study / F.Siebenhaar, F.Degener, T.Zuberbieret al.// J. Allergy Clin.Immunol. 2009. Vol.123, № 3. P. 672–679.
  44. Gimenez-Arnau A., Izquierdo I., Maurer M. The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo-controlled treatment with rupatadine 10 and 20 mg. // J. Eur. Acad.Dermatol.Venereol. 2009. Vol.23, № 9. P. 1088–1091.
  45. Updosingnonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis /S.Guillen-Aguinaga, I.Jauregui Presa, E.Aguinaga-Ontosoet al.// Br. J.Dermatol. 2016. Vol.175, № 6. P. 1153–1165.
  46. Evaluation of cetirizine hydrochloride-based therapeutic strategy for chronic urticarial /KazumitsuSugiura, Satoko Hirai, Tamio Suzuki et al. // Nagoya J. Med. Sci. 2008.Vol.70.P. 97–106.
  47. Randomized, placebo-controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis /A.S.Nayak, W.E.Berger, C.F.LaForce et al. // Allergy Asthma Proc. 2017. Vol.38, № 3. P. 222–230.
  48. Kontou-Fili K., Paleologos G., Herakleous M. Suppression of histamine-induced skin reactions by loratadine and cetirizine diHCl// Eur. J.Clin.Pharmacol. 1989. Vol.36, № 6. P. 617-619.
  49. Double-blind crossover study of high-dose cetirizine in cholinergic urticarial /T.Zuberbier, C.Munzberger, U.Haustein et al. // Dermatology. 1996. Vol.193, № 4. P. 324–327.
  50. Cetirizine at 10 mg once daily in the short term and in the intermediate term was found to be effective in completely suppressing urticaria// Cochrane Database Syst. Rev. 2014. Nov.Vol.14,№ 11. CD006137. doi: 10.1002/14651858.CD006137.pub2.
  51. Efficacy of cetirizine in cholinergic urticarial /T.Zuberbier, W.Aberer, B.Burtinet al.// ActaDerm.Venereol. (Stockh.). 1995. Vol.75. P. 147–149.
  52. Therapeutic effects of cetirizine in delayed pressure urticaria: clinicopathologic findings / K.Kontou-Fili, G.Maniatakou, P.Demaka et al.// J. Am. Acad.Dermatol.1991.Vol.24. P. 1090–1093.
  53. Effect of cetirizine on the inflammatory cells in mosquito bites /A.Karppinen, I.Rantala, A.Vaalasti et al.// Clin. Exp. Allergy. 1996.Vol.26. P. 703–709.
  54. Cetirizines’s fundamental anti-allergic properties are crucial to ETAC’s success.// ETAC Science, 3, 1994.
  55. Behrendt B.G., Ring J. Histamine, antihistamine and atopic eczema // Clin. Exp. Allergy. 1990. Vol.20. (Suppl 4). P. 25–30.
  56. De Vos C. Zyrtec (Cetirizine) – Present EtFutur// Allerg.Immunol. 1989.Vol.21(1Suppl). P. 41–43.
  57. Simons K.J., Simons F.E.R. H1-receptor antagonists: pharmacokinetics and clinical pharmacology / In Simons F.E.R., editor: Histamine and H1-receptor antagonists in allergic disease. New York, Marcel Dekker,1996. P. 175–213.
  58. Hang L., Cheng L., Hong J.The Clinical Use of Cetirizine in the Treatment of Allergic Rhinitis// Pharmacology. 2013. Vol.92. P. 14–25.
  59. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H-1-antihistamine-refractory chronic idiopathic urticarial /S.Saini, K.E.Rosen, H.J.Hsieh et al. // J. Allergy Clin.Immunol. 2011. Vol.128, № 3. P. 567. U195.
  60. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase /M.Maurer, S.Altrichter, T. Bieber et al. // J. Allergy Clin.Immunol. 2011. Vol.128, № 1. P. 202–209.e205.
  61. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study / S.S.Saini, C.Bindslev-Jensen, M. Maurer et al. // J. Invest.Dermatol. 2015. Vol.135, № 1. P. 67–75.
  62. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials / T.Zhao, C.M.Ji, W.J. Yu et al. // J. Allergy Clin.Immunol. 2016. Vol.137, № 6. P. 1742–1750.e1744.
  63. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticarial / M.Metz, S.Altrichter, E.Ardelean et al. //Int. Arch. Allergy Immunol. 2011. Vol.154, № 2. P. 177–180.
  64. Cyclosporine for chronic spontaneous urticaria: a meta-analysis and systematic review /K.Kulthanan, P.Chaweekulrat, C.Komoltri et al. // J. Allergy Clin.Immunol.Pract.2018, Mar–Apr. Vol.6, № 2. P. 586–599.
  65. Doshi D.R., Weinberger M.M. Experience with cyclosporine in children with chronic idiopathic urticaria// Pediatr.Dermatol. 2009. Vol.26, № 4. P. 409–413.
  66. Acute urticaria: clinical aspects and therapeutic responsiveness /T.Zuberbier, J.Ifflander, C.Semmleret al.// ActaDerm.Venereol. 1996. Vol.76, № 4. P. 295–297.
  67. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial /Vena G.A., Cassano N., Colombo D.et al.// J. Am. Acad.Dermatol. 2006. Vol.55, № 4. P. 705–709.
  68. Asero R., Tedeschi A. Usefulness of a Short Course of Oral Prednisone in Antihistamine-Resistant Chronic Urticaria: A Retrospective Analysis // J.Investig.Allergol.Clin.Immunol. 2010. Vol.20, № 5. P. 386–390
  69. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticarial /T.Zuberbier, R.Asero, C.Bindslev-Jensen et al.// Allergy. 2009. Vol.64, № 10. P. 1427–1443.
  70. Rutkowski K., Grattan C.E.H. How to manage chronic urticaria ‘beyond’ guidelines: a practical algorithm // Clin. Exp. Allergy. 2017. Vol.47, № 6. P. 710–718.
  71. Bangsgaard N., Skov L., Zachariae C. Treatment of Refractory Chronic Spontaneous Urticaria with Adalimumab // ActaDerm.Venereol. 2017. Vol.97, № 4.P. 524–525.148.
  72. Sand F.L., Thomsen S.F. TNF-Alpha Inhibitors for Chronic Urticaria: Experience in 20 Patients // J. Allergy (Cairo). 2013. Vol.2013.

Cheburkin AA. Urticaria: modern data on pathogenesis, classification and therapy. Allergology and Immunology in Pediatrics. 2018;54(3):4-13. (In Russ.) https://doi.org/10.24411/2500-1175-2018-00011

For correspondense

A.A. Cheburkin
e-mail: aacaac@yandex.ru.